These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 15725261)

  • 21. [The latest aim of rheumatoid arthritis tratment is complete prevention of destruction].
    Krüger K
    MMW Fortschr Med; 2006 Oct; 148(42):31. PubMed ID: 17621796
    [No Abstract]   [Full Text] [Related]  

  • 22. Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus.
    Rosenau BJ; Schur PH
    J Rheumatol; 2009 Apr; 36(4):753-6. PubMed ID: 19273453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
    Goodemote P; Jamieson B; Hoffman R
    J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
    [No Abstract]   [Full Text] [Related]  

  • 24. [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].
    Manger B; Michels H; Nüsslein HG; Schneider M; Sieper J;
    Z Rheumatol; 2007 Feb; 66(1):72-5. PubMed ID: 17221253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case definition of psoriatic arthritis.
    Taylor WJ; Fellow DE; Helliwell PS
    Lancet; 2000 Dec; 356(9247):2095; author reply 2096. PubMed ID: 11145512
    [No Abstract]   [Full Text] [Related]  

  • 26. Lymphoid aggregation is not lymphoid neogenesis: comment on the article by Klaasen et al.
    Cañete JD; Pablos JL
    Arthritis Rheum; 2010 Sep; 62(9):2825-6. PubMed ID: 20496427
    [No Abstract]   [Full Text] [Related]  

  • 27. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Stable remission of early active rheumatoid arthritis treated with etanercept (Enbrel)].
    Kaliterna DM
    Reumatizam; 2008; 55(2):60-1. PubMed ID: 19024277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recommendations of the German Society of Rheumatology for therapy with tumor necrosis factor inhibitors. Pharmacotherapy Committee of the German Society of Rheumatology].
    Z Rheumatol; 2000 Aug; 59(4):291-2. PubMed ID: 11013988
    [No Abstract]   [Full Text] [Related]  

  • 31. Emerging drugs for psoriatic arthritis.
    Olivieri I; D'Angelo S; Palazzi C; Lubrano E; Leccese P
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):399-414. PubMed ID: 20528612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psoriatic arthritis: biologics seen as new treatment. More aggressive treatment is recommended for psoriatic arthritis, a severe, progressive form of the disease.
    Duke Med Health News; 2012 Apr; 18(4):7. PubMed ID: 22545278
    [No Abstract]   [Full Text] [Related]  

  • 33. The 'disconnect' between synovitis and erosion in rheumatoid arthritis: a result of treatment or intrinsic to the disease process itself?
    McQueen F; Naredo E
    Ann Rheum Dis; 2011 Feb; 70(2):241-4. PubMed ID: 21233504
    [No Abstract]   [Full Text] [Related]  

  • 34. Advances in use of immunomodulatory agents--a rheumatology perspective.
    Her M; Kavanaugh A
    Nat Rev Gastroenterol Hepatol; 2015 Jun; 12(6):363-8. PubMed ID: 25895821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are we coming to terms with tumor necrosis factor inhibition in pregnancy?
    Salmon JE; Alpert D
    Arthritis Rheum; 2006 Aug; 54(8):2353-5. PubMed ID: 16868990
    [No Abstract]   [Full Text] [Related]  

  • 36. Synovial synoviolin in relation to response to TNF blockade in patients with rheumatoid arthritis and psoriatic arthritis.
    Klaasen R; Wijbrandts CA; van Kuijk AW; Pots D; Gerlag DM; Tak PP
    Ann Rheum Dis; 2012 Jul; 71(7):1260-1. PubMed ID: 22345123
    [No Abstract]   [Full Text] [Related]  

  • 37. Patient-tailored therapy in rheumatoid arthritis: an editorial review.
    Scherer HU; Dörner T; Burmester GR
    Curr Opin Rheumatol; 2010 May; 22(3):237-45. PubMed ID: 20177384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Arthritis psoriatica].
    de Rie MA; van Kuijk AW; Goedkoop AY; Tak PP
    Ned Tijdschr Geneeskd; 2007 Aug; 151(31):1716-22. PubMed ID: 17784693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.